JP2016518321A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518321A5
JP2016518321A5 JP2016501214A JP2016501214A JP2016518321A5 JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5 JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016501214 A JP2016501214 A JP 2016501214A JP 2016518321 A5 JP2016518321 A5 JP 2016518321A5
Authority
JP
Japan
Prior art keywords
range
rfviii
formulation
ppm
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023357 external-priority patent/WO2014150477A1/en
Publication of JP2016518321A publication Critical patent/JP2016518321A/ja
Publication of JP2016518321A5 publication Critical patent/JP2016518321A5/ja
Pending legal-status Critical Current

Links

JP2016501214A 2013-03-15 2014-03-11 組み換え因子viii配合物 Pending JP2016518321A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US61/799,495 2013-03-15
US201361869191P 2013-08-23 2013-08-23
US61/869,191 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (2)

Publication Number Publication Date
JP2016518321A JP2016518321A (ja) 2016-06-23
JP2016518321A5 true JP2016518321A5 (https=) 2017-04-13

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501214A Pending JP2016518321A (ja) 2013-03-15 2014-03-11 組み換え因子viii配合物

Country Status (17)

Country Link
US (1) US20160030524A1 (https=)
EP (1) EP2970430A4 (https=)
JP (1) JP2016518321A (https=)
KR (1) KR20150132449A (https=)
CN (1) CN105209487A (https=)
AU (1) AU2014237111B2 (https=)
BR (1) BR112015022730A2 (https=)
CA (1) CA2905739A1 (https=)
HK (1) HK1213273A1 (https=)
MX (1) MX2015012905A (https=)
PE (1) PE20160121A1 (https=)
RU (1) RU2015144076A (https=)
SG (2) SG10201803999UA (https=)
TW (1) TW201521761A (https=)
UY (1) UY35412A (https=)
WO (1) WO2014150477A1 (https=)
ZA (1) ZA201507684B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
KR20010101901A (ko) * 1999-02-01 2001-11-15 모리 데쯔지 음극선관 및 그 제조방법
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
ES2331909T3 (es) * 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
MX339060B (es) * 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Similar Documents

Publication Publication Date Title
JP2016518321A5 (https=)
JP2016515515A5 (https=)
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
UA125223C2 (uk) СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
GEAP202114794A (en) Antibody neutralizing human respiratory syncytial virus
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
MX2021004015A (es) Compuestos de aminoacidos y metodos de uso.
WO2015165374A1 (en) Methods and compositions for modulating the immune system with arginase i
JP2009017881A5 (https=)
JP2019504086A5 (https=)
JP2010511665A5 (https=)
ES2791954T3 (es) Nuevo antagonista de TLR4
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
JP2015500827A5 (https=)
NZ700686A (en) Uses of casein compositions
JP2016520075A5 (https=)
JP2012136518A5 (https=)
RU2015144076A (ru) Композиции рекомбинантного фактора viii
WO2018134389A1 (en) Methods and compositions for treating infections
JP2016520534A5 (https=)
MX2020006328A (es) Composición inmunogénica.
JP2015519359A5 (https=)
RU2014146772A (ru) Новые ротавирусные вакцинные композиции и способ получения вышеуказанных композиций